ramucirumab,pembrolizumab
eli lilly,merck
['pembro', 'ramucirumab', 'improve ', 'lung-map', 'nsclc', 'lung', 'sclc']
lung-map at #asco22 shows os benefit for pembro + ramucirumab in nsclc after prior ici/chemo. this is the first trial in the ici refractory setting to improve overall survival compared to standard of care, said lead study author : 
Editor for @PatientPower and @OBRtweets | she/her